Our technology

NemaGen's recent breakthrough has identified a requirement for the metabolic enzyme, carbonic anhydrase 1 (Car1) in mast cell development. We are advancing these findings by developing novel chemical compounds to target Car1 and prevent mast cell-mediated inflammation. This innovative program seeks to develop much needed treatments for allergic inflammation, mastocytosis and other mast cell-related diseases. NemaGen currently has an oral preclinical lead stage candidate that meets efficacy and safety criteria. 

  NemaGen is also developing a therapeutic targeted at carbonic anhydrase 4 (Car4).  Car4 is a lineage defining cell surface marker of alveolar macrophages. Importantly, NemaGen has identified that Car4 deficiency leads to spontaneous emphysema and fibrosis, and strikingly, Car4 treatment protects against lung damage in murine models of emphysema. Notably, Car4 is amongst the highest down-regulated proteins in patients with COPD and emphysema, and is highly down-regulated in patients with idiopathic pulmonary fibrosis (IPF). We are advancing these findings by developing a novel Car4-derived therapeutic to treat pulmonary inflammation for patients with COPD, emphysema, and IPF. 

NemaGen's cutting-edge neuroimmunology studies have revealed that the neuropeptide NMB is a potent inhibitor of lung inflammation. Lung diseases including COVID-19 represent the leading cause of death in the world and novel therapeutics are desperately needed to prevent lung inflammation.  This program is advancing NMB delivery strategies  to treat both acute and chronic inflammatory responses in the lung.